RT Journal Article
SR Electronic
T1 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2427
VO 44
IS Suppl 58
A1 David Halpin
A1 Eric Bateman
A1 Pierluigi Paggiaro
A1 Eugene Bleecker
A1 Michael Engel
A1 Petra Moroni-Zentgraf
A1 Hendrik Schmidt
A1 Huib Kerstjens
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P2427.abstract
AB Background: A reduction in asthma exacerbation risk may provide improvements in clinical burden, patient experience and healthcare costs. In Phase III trials, once-daily tiotropium Respimat (tioR) add-on to at least ICS improved lung function in symptomatic asthma patients. We investigated exacerbation risk in each trial.Methods: Five Phase III double-blind, placebo-controlled, parallel-group trials in patients with symptomatic asthma. Patients received tioR 5 µg or placebo Respimat (pboR) as add-on to at least ICS maintenance therapy (Table). Pre-planned co-primary or secondary end points: time to first severe exacerbation; time to any asthma worsening.Results: Mean baseline % of predicted FEV1, ACQ-7 score and ICS dose (µg) were: 56.0±13.1, 2.6±0.7, 1198±539 (PrimoTinA); 75.1±11.5, 2.2±0.5, 660±213 (MezzoTinA); 77.7±11.9, 2.1±0.4, 381±78 (GraziaTinA). TioR 5 µg reduced severe asthma exacerbation risk by at least 21% in all three severity cohorts (Table) and asthma worsening risk vs pboR in all trials, with a statistically significant reduction in PrimoTinA.Conclusion: Once-daily tiotropium Respimat 5 µg add-on to at least ICS maintenance therapy consistently reduced exacerbations across asthma severities and so may be a beneficial add-on option to reduce current and future exacerbation risk.